diarrhea while taking tirzepatide on (Mounjaro) affects approximately 23–31% of patients and is typically mild to moderate, transient, and most common during dose escalation. , It rarely requires discontinuation Tirzepatide and Diarrhea - What

This extended satiety makes it naturally easier to manage portion sizes and avoid unnecessary snacking, aligning with the bodys natural pace of digestion and leading to sustainable behavioral changes

Every meal is designed to hit the glp-1 protein target even on days when appetite is minimal

Reduced appetite, smaller meals, and changes in digestion can all make it harder to consistently maintain hydration, protein intake, vitamins, and minerals over time

FDA The FDA has not endorsed any alternative dosing protocol and has issued warnings about compounded GLP-1 formulations, which are often marketed for microdosing purposes

You will likely start at 0.25 mg and slowly increase over several months